Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1989 1
1990 2
1992 1
1996 1
1998 1
1999 1
2000 1
2001 1
2002 1
2003 3
2004 1
2006 2
2007 3
2008 4
2009 4
2010 8
2011 6
2012 5
2013 10
2014 7
2015 6
2016 7
2017 9
2018 13
2019 29
2020 32
2021 25
2022 22
2023 23
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, Liu LT, Luo DH, Li YF, Deng SW, Guo L, Zeng MS, Cai XY, Liu SL, Sun XS, Li XY, Li SC, Chen QY, Tang LQ, Mai HQ. Yuan L, et al. Among authors: sun xs. Nat Commun. 2023 Aug 14;14(1):4893. doi: 10.1038/s41467-023-40402-x. Nat Commun. 2023. PMID: 37580352 Free PMC article. Clinical Trial.
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J. Tao Y, et al. Among authors: sun xs. Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28. Ann Oncol. 2023. PMID: 36522816 Free article. Clinical Trial.
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J. Tao Y, et al. Among authors: sun xs. Eur J Cancer. 2023 Apr;183:24-37. doi: 10.1016/j.ejca.2022.12.015. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36796234 Free article. Clinical Trial.
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu LT, Liu H, Huang Y, Yang JH, Xie SY, Li YY, Guo SS, Qi B, Li XY, Chen DP, Jin F, Sun XS, Yang ZC, Liu SL, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Qiu F, Yang Q, Liang YJ, Jia GD, Wen DX, Yan JJ, Zhao C, Chen QY, Sun R, Tang LQ, Mai HQ. Liu LT, et al. Among authors: sun xs. Lancet Oncol. 2023 Jul;24(7):798-810. doi: 10.1016/S1470-2045(23)00232-2. Epub 2023 Jun 5. Lancet Oncol. 2023. PMID: 37290468 Clinical Trial.
5-[(2-Hy-droxy-eth-yl)(meth-yl)amino]-thio-phene-2-carbaldehyde.
Sun XS, Shao NQ, Li DD. Sun XS, et al. Acta Crystallogr Sect E Struct Rep Online. 2014 May 31;70(Pt 6):o724. doi: 10.1107/S1600536814012021. eCollection 2014 Jun 1. Acta Crystallogr Sect E Struct Rep Online. 2014. PMID: 24940293 Free PMC article.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J. Sun XS, et al. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3. Lancet Oncol. 2020. PMID: 32758455 Clinical Trial.
Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.
Tao Y, Sun XS, Pointreau Y, Tourneau CL, Sire C, Gollmer K, Crompton P, Bourhis J. Tao Y, et al. Among authors: sun xs. Future Oncol. 2023 Aug;19(26):1769-1776. doi: 10.2217/fon-2023-0322. Epub 2023 Jul 13. Future Oncol. 2023. PMID: 37439181 Free article. Clinical Trial.
Self-Assembling Peptide Solution Accelerates Hemostasis.
Carter T, Qi G, Wang W, Nguyen A, Cheng N, Ju YM, Lee SJ, Yoo JJ, Atala A, Sun XS. Carter T, et al. Among authors: sun xs. Adv Wound Care (New Rochelle). 2021 Apr;10(4):191-203. doi: 10.1089/wound.2019.1109. Epub 2020 Sep 10. Adv Wound Care (New Rochelle). 2021. PMID: 32716728 Free PMC article.
Chemoradiation in anaplastic thyroid carcinomas.
Sun XS, Sun SR, Guevara N, Fakhry N, Marcy PY, Lassalle S, Peyrottes I, Bensadoun RJ, Lacout A, Santini J, Cals L, Bosset JF, Garden AS, Thariat J. Sun XS, et al. Crit Rev Oncol Hematol. 2013 Jun;86(3):290-301. doi: 10.1016/j.critrevonc.2012.10.006. Epub 2012 Dec 4. Crit Rev Oncol Hematol. 2013. PMID: 23218594 Review.
211 results